Learning Objectives:

1.  Review the history and biology of the Ras oncogene.

2.  Discuss prior drug development strategies in anti-Ras therapy.

3.  Present recent trial data on a KRAS (G12C) inhibitor.

Session date: 
02/13/2020 - 8:00am to 9:15am CST
Evanston Hospital, Room G870
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Michael J. Breen, M.D., Ph.D.